TwinBeech Capital’s Immunovant IMVT Stock Holding History

TwinBeech Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-102,036	Closed	-$1.74M	–	807
2025 Q1	$1.74M	Buy	102,036 +89,347	+704%	+$1.87M	0.03%	411
2024 Q4	$314K	Buy	+12,689	New	+$360K	0.01%	512
2024 Q3	–	Sell	-30,859	Closed	-$815K	–	767
2024 Q2	$815K	Buy	30,859 +23,458	+317%	+$667K	0.02%	419
2024 Q1	$239K	Buy	+7,401	New	+$270K	﹤0.01%	494
2023 Q3	–	Sell	-109,448	Closed	-$2.08M	–	759
2023 Q2	$2.08M	Buy	+109,448	New	+$2.04M	0.04%	374

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

TwinBeech Capital's IMVT Position: Q2 2025 in Review

TwinBeech Capital sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 102,036 shares — an estimated $1.74M sold.

TwinBeech Capital first reported a position in IMVT in Q2 2023 and held it in 5 quarters. The position peaked at $2.08M in Q2 2023. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

TwinBeech Capital reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
TwinBeech Capital sold 102,036 Immunovant shares in Q2 2025, an estimated $1.74M.
TwinBeech Capital first reported a position in Immunovant in Q2 2023 and held it in 5 quarters.
TwinBeech Capital's Immunovant position peaked at $2.08M in Q2 2023.
168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.